Thank you to Business France North America and French Healthcare for highlighting our innovative Intraoperative Cell Recovery technology and its benefits to patients and healthcare system: « same by i-SEP »
[#FrenchHealthcare] In hemorrhagic or high-risk hemorrhagic surgery, i-SEP’s device collects the blood lost by the patient, washes it, and salvages the #bloodcells, including both red blood cells and platelets. The cells are then retransfused to the patient, either instead of or in addition to blood bank transfusions (allogeneic transfusions).
“The benefit is threefold: not only for the patient but for the health system as well, considering that a platelet concentrate costs up to €750. It will also reduce reliance on blood product inventories, especially platelet inventory, which are constantly under strain,” says Sylvain Picot, CEO and co-founder of i-SEP.
The device is expected to obtain CE approval (European marketing authorization) in mid-2022. Discussions have begun with the FDA with a view to registering it in the US.
🔎Read the full article:
#patientcentricity #healthcare #PatientBloodManagement #IOCS